Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1385/1-59259-669-X:125 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Epidemiological and genetic analysis of SEN virus infections in hemodialysis patients and healthy individuals in Tehran, Iran.
Diagn Microbiol Infect Dis
September 2025
Department of Mycobacteriology and Pulmonary Research, Pasteur Institute of Iran, Tehran, Iran; Microbiology Research Center (MRC), Pasteur Institute of Iran, Tehran, Iran. Electronic address:
This case-control study investigated the epidemiological and genetic distribution of SEN virus (SENV) infections among 1,576 hemodialysis (HD) patients and 1,000 age- and gender-matched healthy individuals in Iran between 2017 and 2024. Nested PCR was utilized to amplify the ORF1 gene, facilitating the identification and sequencing of SENV genotypes D and H. The results demonstrated a significantly higher prevalence of SENV among HD patients (45.
View Article and Find Full Text PDFHepatitis B virus rtCYE/rtCYEI mutations may contribute limited tenofovir resistance: Analysis of a large sample of Chinese patients.
World J Hepatol
August 2025
Senior Department of Infectious Diseases, The Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing 100039, China.
Background: Whether rtS106C+H126Y+D134E/rtS106C+H126Y+D134E+L269I (rtCYE/rtCYEI) mutations in the hepatitis B virus (HBV) reverse-transcriptase (RT) region are associated with tenofovir disoproxil fumarate (TDF) resistance is controversial.
Aim: To evaluate the presence of the rtCYE/rtCYEI mutations in a large cohort of Chinese patients with chronic HBV infection.
Methods: A total of 28236 patients who underwent drug resistance testing at the Fifth Medical Center of Chinese PLA General Hospital from 2007 to 2019 were enrolled.
A novel synthetic bile acid derivative inhibits hepatitis B virus infection at entry step by interfering with the oligomerization of sodium taurocholate co-transporting polypeptide.
Antiviral Res
August 2025
Division of Infectious Disease Control, Center for Infectious Diseases, Kobe University Graduate School of Medicine, Kobe, Japan. Electronic address:
Hepatitis B virus (HBV) infection is a major global health burden worldwide despite the availability of an effective vaccine and effective anti-HBV drugs. The currently approved anti-HBV drugs-i.e.
View Article and Find Full Text PDFHyperendemicity and genotype diversity of hepatitis B virus among patients attending the University of Abuja Teaching Hospital, Nigeria.
GMS Hyg Infect Control
July 2025
Department of Medical Laboratory Science, Faculty of Allied Health Sciences, College of Medical Sciences, Ahmadu Bello University, Zaria, Nigeria.
Background: Hepatitis B virus (HBV) infection remains a significant global public health issue, particularly in sub-Saharan Africa, due to inadequate healthcare and research into its genetic epidemiology. This study aims to determine the frequency of HBV antigens, antibodies, and genotypes among febrile patients attending the University of Abuja Teaching Hospital (UATH), Nigeria.
Methods: This cross-sectional study enrolled 100 patients, whose blood samples were collected and screened for HBV surface antigen (HBsAg) and four other structural antigens and antibodies by Lateral Flow Assay.
Fatal Hepatitis B Reactivation in Absence of Antibody to Hepatitis B Core Antigen in a Lymphoma Patient.
J Med Virol
July 2025
IHU Méditerranée Infection, Marseille, France.
Reactivations of hepatitis B virus (HBV) infection in severely immunocompromised patients with serological profiles of past hepatitis B are non-exceptional and potentially severe or fatal events. The preventive and pre-emptive detection of this serological status is compromised in the absence of antibodies to hepatitis B core antigen (anti-HBc), observed in a very small number of cases of HBV infection. Here, we describe the case of a patient with a serological profile indicating a HBV vaccination although the patient did not report previous vaccination, following lymphoma and chemotherapy including rituximab.
View Article and Find Full Text PDF